Inventor · disambiguated record
Eric Krauland
Also filed as: KRAULAND ERIC · KRAULAND ERIC M · KRAULAND ERIC MARK
22 granted patents·17 pending applications·121 citations·filing 2005–2024
94Inventor score
Files withMERRIMACK PHARMACEUTICALS INC10ADIMAB LLC8MERSANA THERAPEUTICS INC6UNIV TEXAS4GENENTECH INC3
Top patents by PatentIndex Score
39 records- 0196US9738720B2Monoclonal antibodies against HER2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2016·Granted Aug 22, 2017·10 cites·30 claims
- 0294US9555112B2Monoclonal antibodies against HER2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2015·Granted Jan 31, 2017·13 cites·42 claims
- 0393US8957034B2Drugs and gene carrier particles that rapidly move through mucous barriersHANES JUSTIN·Filed 2005·Granted Feb 17, 2015·60 cites·28 claims
- 0489US9226964B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Jan 5, 2016·9 cites·37 claims
- 0589US2025066489A1Monoclonal antibodies against her2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0684US11390964B2Polyclonal mixtures of antibodies, and methods of making and using themADIMAB LLC·Filed 2020·Granted Jul 19, 2022·1 cites·10 claims
- 0784US9044460B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofBUKHALID RAGHIDA·Filed 2011·Granted Jun 2, 2015·9 cites·12 claims
- 0883US11008403B2Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of useGENENTECH INC·Filed 2015·Granted May 18, 2021·3 cites·25 claims
- 0982US9458245B2ANTI-C-MET tandem Fc bispecific antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Oct 4, 2016·6 cites·3 claims
- 1082US2023265197A1Monoclonal antibodies against her2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1181US12258679B2Polyclonal mixtures of antibodies, and methods of making and using themADIMAB LLC·Filed 2022·Granted Mar 25, 2025·0 cites·16 claims
- 1281US2025059282A1Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use thereforUNIV TEXAS·Filed 2024·Application pending·0 cites
- 1380US2025129167A1Dual specificity antibodies to pd-l1 and pd-l2 and methods of use thereforUNIV TEXAS·Filed 2024·Application pending·0 cites
- 1478US11542330B2Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and useADIMAB LLC·Filed 2018·Granted Jan 3, 2023·1 cites·19 claims
- 1576US10684289B2Polyclonal mixtures of antibodies, and methods of making and using themADIMAB LLC·Filed 2014·Granted Jun 16, 2020·1 cites·10 claims
- 1675US11485795B2Anti-PCSK9 antibody and use thereofINNOVENT BIOLOGICS SUZHOU CO LTD·Filed 2017·Granted Nov 1, 2022·1 cites·29 claims
- 1774US11518812B2Monoclonal antibodies against HER2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2019·Granted Dec 6, 2022·0 cites·14 claims
- 1873US8450247B2Cell display librariesPEELLE BEAU R·Filed 2005·Granted May 28, 2013·5 cites·31 claims
- 1969US2017313778A1Monoclonal antibodies against her2 epitope and methods of use thereofMERSANA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2069US2023151097A1Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and useADIMAB LLC·Filed 2022·Application pending·0 cites
- 2168US8569226B2High affinity metal-oxide binding peptides with reversible bindingKRAULAND ERIC MARK·Filed 2008·Granted Oct 29, 2013·2 cites·42 claims
- 2268US2022396622A1Fc variants with reduced effector functionADIMAB LLC·Filed 2022·Application pending·0 cites
- 2367US11746160B2Antibodies against BACE1 and use thereof for neural disease immunotherapyGENENTECH INC·Filed 2020·Granted Sep 5, 2023·0 cites·6 claims
- 2467US2021052507A1Drugs and gene carrier particles that rapidly move through mucous barriersUNIV JOHNS HOPKINS·Filed 2020·Application pending·0 cites
- 2566US12187799B2Dual specificity antibodies to PD-L1 and PD-L2 and methods of use thereforUNIV TEXAS·Filed 2019·Granted Jan 7, 2025·0 cites·17 claims
- 2666US2018344656A1Drugs and gene carrier particles that rapidly move through mucous barriersUNIV JOHNS HOPKINS·Filed 2018·Application pending·0 cites
- 2765US12134648B2Dual specificity antibodies to human PD-L1 and PD-L2 and methods of use thereforUNIV TEXAS·Filed 2019·Granted Nov 5, 2024·0 cites·16 claims
- 2865US2014234314A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2961US10072299B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Sep 11, 2018·0 cites·21 claims
- 3061US9902999B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 27, 2018·0 cites·21 claims
- 3161US9885087B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 6, 2018·0 cites·21 claims
- 3260US2021087271A1Fc variants with reduced effector functionADIMAB LLC·Filed 2020·Application pending·0 cites
- 3358US2016256404A1Drugs and Gene Carrier Particles That Rapidly Move Through Mucous BarriersUNIV JOHNS HOPKINS·Filed 2015·Application pending·0 cites
- 3457US10882920B2Antibodies against BACE1 and use thereof for neural disease immunotherapyGENENTECH INC·Filed 2015·Granted Jan 5, 2021·0 cites·21 claims
- 3551US2023265134A1Ch1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the sameADIMAB LLC·Filed 2020·Application pending·0 cites
- 3649US2017081421A1Anti-c-met tandem fc bispecific antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3747US2015368361A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3846US2016002339A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3942US2017314079A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Eric Krauland files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →